KMDA Q3 2022 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$495M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$32M+39.9% YoY

Gross Profit

$13M39.9% margin

Operating Income

$3M8.0% margin

Net Income

$484,0001.5% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$366,000

Balance Sheet

Total Assets

$320M

Total Liabilities

$147M

Stockholders' Equity

$173M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$23M	+39.9%
Gross Profit	$13M	$6M	+124.6%
Operating Income	$3M	-$804,000	+418.7%
Net Income	$484,000	-$845,000	+157.3%